UY36561A - Nuevas proteínas específicas para pioverdina y pioquelina - Google Patents

Nuevas proteínas específicas para pioverdina y pioquelina

Info

Publication number
UY36561A
UY36561A UY0001036561A UY36561A UY36561A UY 36561 A UY36561 A UY 36561A UY 0001036561 A UY0001036561 A UY 0001036561A UY 36561 A UY36561 A UY 36561A UY 36561 A UY36561 A UY 36561A
Authority
UY
Uruguay
Prior art keywords
muteins
pioverdina
pioquelina
specific proteins
new specific
Prior art date
Application number
UY0001036561A
Other languages
English (en)
Inventor
Dr Corvey Carsten
Stump Heike
Dr Kruip Jochen
Calandra Bernard
Rey Astrid
Karst Nathalie
Mourez Michael
Fraisse Laurent
Dr Rothe Christine
Dr Allersdorfer Andrea
Dr Wiedenmann Alexander
Dr Hinner Marion
Dr Lunde Bradley
Dr Jensen Kristian
Dr Hülsmeyer Martin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY36561A publication Critical patent/UY36561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente descripción proporciona muteínas de hNGAL que se unen con un miembro de la familia de pioverdina o pioquelina que pueden usarse en aplicaciones farmacéuticas para inhibir o reducir el crecimiento de P. aeruginosa. También se proporcionan métodos para preparar muteínas de unión a pioverdina o a pioquelina,composiciones que comprenden una o más muteínas así como moléculas de ácido nucleico que codifican dichas muteínas, métodos para la generación de dichas muteínas y moléculas de ácido nucleico. La solicitud describe usos terapéuticos y/o de diagnóstico de estas muteínas así como composiciones que comprenden una o más de dichas muteínas.
UY0001036561A 2015-02-18 2016-02-18 Nuevas proteínas específicas para pioverdina y pioquelina UY36561A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18

Publications (1)

Publication Number Publication Date
UY36561A true UY36561A (es) 2016-09-30

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036561A UY36561A (es) 2015-02-18 2016-02-18 Nuevas proteínas específicas para pioverdina y pioquelina

Country Status (28)

Country Link
US (8) US9884898B2 (es)
EP (1) EP3259282A1 (es)
JP (1) JP6843754B2 (es)
KR (1) KR20170116158A (es)
CN (1) CN107660211A (es)
AR (1) AR103714A1 (es)
AU (1) AU2016221816B2 (es)
BR (1) BR112017017530A2 (es)
CA (1) CA2976687A1 (es)
CL (1) CL2017002082A1 (es)
CO (1) CO2017009433A2 (es)
CR (1) CR20170425A (es)
DO (1) DOP2017000191A (es)
EA (1) EA035824B1 (es)
EC (1) ECSP17061751A (es)
GT (1) GT201700184A (es)
HK (1) HK1245293A1 (es)
IL (1) IL254013A0 (es)
MA (1) MA41072A1 (es)
MX (1) MX2017010628A (es)
PE (1) PE20171652A1 (es)
PH (1) PH12017501473A1 (es)
SG (1) SG11201706621SA (es)
TN (1) TN2017000348A1 (es)
TW (1) TW201636364A (es)
UY (1) UY36561A (es)
WO (1) WO2016131804A1 (es)
ZA (1) ZA201705257B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660510A3 (en) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
BR112016027024A2 (pt) 2014-05-22 2017-10-31 Pieris Pharmaceuticals Gmbh polipeptídeos de ligação específica e seus usos
US10526382B2 (en) 2015-01-28 2020-01-07 Pieris Pharmaceuticals Gmbh Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof
AU2016221816B2 (en) * 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN108112253B (zh) 2015-05-18 2022-09-23 皮里斯制药有限公司 抗癌融合多肽
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
BR112018010887A2 (pt) 2015-11-30 2018-11-21 Pieris Australia Pty Ltd polipeptídeo de fusão
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN113226360A (zh) * 2018-07-19 2021-08-06 科罗拉多大学评议会 用于肠杆菌素治疗铁缺乏和相关贫血的新用途的方法、***和组合物
EP3946417A1 (en) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
AU2016221816B2 (en) * 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
TN2017000348A1 (en) 2019-01-16
US20180030101A1 (en) 2018-02-01
SG11201706621SA (en) 2017-09-28
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
US10118952B2 (en) 2018-11-06
US9884898B2 (en) 2018-02-06
US20170267734A1 (en) 2017-09-21
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
EA201791841A1 (ru) 2018-01-31
US20180371037A1 (en) 2018-12-27
MA41072A1 (fr) 2018-10-31
JP6843754B2 (ja) 2021-03-17
AU2016221816A1 (en) 2017-10-12
JP2018506979A (ja) 2018-03-15
CA2976687A1 (en) 2016-08-25
PH12017501473A1 (en) 2018-01-29
ZA201705257B (en) 2019-06-26
PE20171652A1 (es) 2017-11-13
US20180346532A1 (en) 2018-12-06
WO2016131804A1 (en) 2016-08-25
EA035824B1 (ru) 2020-08-17
KR20170116158A (ko) 2017-10-18
HK1245293A1 (zh) 2018-08-24
CL2017002082A1 (es) 2018-04-27
CO2017009433A2 (es) 2017-11-30
BR112017017530A2 (pt) 2018-04-17
DOP2017000191A (es) 2017-09-29
GT201700184A (es) 2018-10-24
ECSP17061751A (es) 2017-10-31
US10329334B2 (en) 2019-06-25
MX2017010628A (es) 2017-12-07
AR103714A1 (es) 2017-05-31
AU2016221816B2 (en) 2020-07-02
CN107660211A (zh) 2018-02-02
TW201636364A (zh) 2016-10-16
US20180037618A1 (en) 2018-02-08
US10072056B2 (en) 2018-09-11
CR20170425A (es) 2017-11-22
US20180371038A1 (en) 2018-12-27
US10065998B2 (en) 2018-09-04

Similar Documents

Publication Publication Date Title
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
CO2017000558A2 (es) Variantes de proteínas de unión al factor h
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP17013904A (es) Angiopoietin-like 4 antibodies and methods of use
GT201800102A (es) Polipéptidos que inhiben cd4ol
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
ECSP18008488A (es) Moléculas de fusión
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
CL2018001661A1 (es) Moléculas de anticuerpo que se unen a tnf alfa
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104